Buck Wealth Strategies LLC Purchases 2,732 Shares of Jazz Pharmaceuticals PLC $JAZZ

Buck Wealth Strategies LLC lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 53.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,876 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,732 shares during the period. Buck Wealth Strategies LLC’s holdings in Jazz Pharmaceuticals were worth $1,339,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its stake in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the last quarter. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $36,000. Danske Bank A S purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $40,000. Quent Capital LLC bought a new position in Jazz Pharmaceuticals in the 3rd quarter worth $44,000. Finally, Geneos Wealth Management Inc. raised its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares of the company’s stock, valued at $73,281,921. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Norbert G. Riedel sold 3,415 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the transaction, the director directly owned 7,024 shares in the company, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 74,015 shares of company stock worth $14,180,486 over the last 90 days. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.5%

Jazz Pharmaceuticals stock opened at $225.79 on Friday. The business has a fifty day moving average of $192.62 and a two-hundred day moving average of $172.95. The firm has a market cap of $14.17 billion, a P/E ratio of -11,283.86, a P/E/G ratio of 0.41 and a beta of 0.27. The company has a quick ratio of 1.67, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a twelve month low of $97.56 and a twelve month high of $230.40.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. On average, analysts forecast that Jazz Pharmaceuticals PLC will post 20.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on JAZZ shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Piper Sandler lifted their target price on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Barclays boosted their target price on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $230.56.

Read Our Latest Stock Analysis on Jazz Pharmaceuticals

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Further Reading

• Five stocks we like better than Jazz Pharmaceuticals

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).